Active	Status	Sponsor type	Region	Phase	Filter
15 Active 6 Inactive 21 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bug, Gesine
IDUNN, NCT04629833 / 2019-001462-15: Treatment of Steroid-Refractory Acute Graft-versus-host Disease with Mesenchymal Stromal Cells Versus Best Available Therapy	Recruiting	3	210	Europe	MC0518, BAT	medac GmbH	Steroid-refractory Acute Graft-versus-host Disease	08/27	08/30
PHOEBUS, NCT05762211: Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications ( Trial)	Recruiting	2	387	Europe	Pooled allogeneic fecal microbiotherapy, MaaT033, Placebo	MaaT Pharma	Transplant Complication	10/26	02/27
Kobbe, Guido
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL	Active, not recruiting	3	240	Europe, Canada, US, RoW	Brentuximab vedotin, Rituximab, Lenalidomide, Placebo	Seagen Inc.	Diffuse Large B-cell Lymphoma	05/25	04/27